Skip to content
buyWeak

Andrea S. James bought $46k of IMDX

Chief Financial Officer at Oncocyte Corp. 20,000 shares at an average of $2.29, traded Dec 5, 2024, filed Dec 9, 2024.

Conviction score
38
Value
$46k
20,000 shares
Holdings after
53,670
+59% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CFO
    +22
  • Trade size
    $46k at market
    +6
  • Relative to holdings
    Holdings up 59%
    +10
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001493152-24-049195, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 5, 2024POpen-market purchase
Common Stock, no par value
+20,000$2.29$46k53,670Dec 9, 2024

Related signals

Other insiders at Oncocyte Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
57Moderate
IMDXbuy 2
Oncocyte Corp
Andrea S. James
Chief Financial Officer
$200k
97,561 shares
+182%
50Moderate
IMDXbuy 2
Oncocyte Corp
Broadwood Partners, L.p.
owner
$11M
5,165,695 shares
+83%
30Weak
IMDXbuy 2
Oncocyte Corp
Patrick W Smith
owner
$192k
90,219 shares
+5%
31Weak
IMDXbuy 2
Oncocyte Corp
Andrew Arno
director
$26k
12,500 shares
+18%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Andrea S. James bought $46k of IMDX | InsiderTell